Helios Universitaetsklinikum Wuppertal

At Helios Universitaetsklinikum Wuppertal, researchers are advancing care for blood‑related cancers such as acute myeloid leukemia and myelodysplastic syndrome. Clinical studies aim to evaluate novel targeted agents and combination chemotherapy to improve survival and reduce treatment‑related toxicity.

• Targeted IDH1/IDH2 inhibition combined with chemotherapy
• FLT3‑directed therapy versus standard treatment
• Venetoclax‑based regimens for newly diagnosed disease
• Assessment of event‑free survival in molecularly defined subgroups

The department conducts 12 active trials with a team of 24 investigators, reflecting a strong commitment to hematologic research.

The oncology program focuses on solid tumors, notably ER‑positive/HER2‑negative early breast cancer and prostate cancer. Trials are designed to test next‑generation endocrine therapies and hormone‑based strategies to prevent recurrence and prolong disease‑free survival.

• Comparative study of oral selective estrogen receptor degraders with standard aromatase inhibition
• Adjuvant endocrine therapy combined with CDK4/6 inhibition
• Evaluation of distant metastasis‑free survival in ctDNA‑positive breast cancer
• Investigation of novel androgen receptor targeting in metastatic hormone‑sensitive prostate cancer

These investigations contribute to personalized treatment pathways for patients across the Wuppertal region.

Investigations into immune‑mediated conditions include moderate‑to‑severe ulcerative colitis and atopic dermatitis. The goal is to assess biologic agents that can induce durable remission while minimizing systemic side effects.

• Efficacy of IL‑23 inhibition in pediatric ulcerative colitis
• Head‑to‑head comparison of novel anti‑IL‑13 antibody versus placebo in atopic dermatitis
• Long‑term safety monitoring of systemic immunomodulators
• Biomarker‑driven response assessment in inflammatory bowel disease

The department’s multidisciplinary approach integrates gastroenterology and dermatology expertise.

Research on functional gastrointestinal disorders targets functional constipation in infants and toddlers. Studies evaluate the safety and therapeutic benefit of new secretagogues to improve bowel habits without invasive procedures.

• Dose‑finding study of a guanylate cyclase‑C agonist in children under two years
• Parent‑reported outcome measures for stool frequency and consistency
• Pharmacokinetic profiling in the pediatric population
• Comparison with standard laxative therapy

These pediatric trials address an unmet need for age‑appropriate treatments in early childhood.

The clinic’s urologic oncology efforts concentrate on prostate cancer, particularly metastatic hormone‑sensitive disease. Clinical programs explore intensified chemotherapy schedules and novel androgen‑axis inhibitors to extend survival.

• Randomized evaluation of weekly versus bi‑weekly docetaxel combined with androgen deprivation therapy
• Assessment of quality‑of‑life outcomes during intensified treatment
• Exploratory analysis of molecular markers predicting response
• Integration of imaging biomarkers in treatment monitoring

Collaboration with the department of radiology enhances precision in disease assessment.

Metabolic research at the site includes investigations into nutrition‑related complications of cancer therapy, aiming to support patient resilience and recovery. Trials examine dietary interventions and metabolic modulators to mitigate treatment‑induced weight loss.

• Nutritional supplementation during intensive chemotherapy
• Metabolic profiling to identify patients at risk of cachexia
• Effect of probiotic administration on gut microbiome balance
• Evaluation of energy expenditure in survivors of hematologic malignancies

The multidisciplinary team includes dietitians and metabolic specialists.

Dermatology studies focus on severe atopic dermatitis and hand eczema, testing targeted antibodies that modulate immune pathways to reduce skin inflammation and improve quality of life.

• Phase 3 trial of anti‑IL‑33 monoclonal antibody versus placebo
• Patient‑reported outcomes on itch severity and skin barrier function
• Safety assessment over 24‑week treatment period
• Comparison with existing systemic therapies

The research integrates dermatologic assessment tools for robust efficacy evaluation.